TICKERNERD
Menu
CRMDCRMDHealthcare · Biotechnology

CRMD Stock Forecast: CorMedix, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$7.54
−7.37% on the day

The 5 Wall Street analysts covering CorMedix, Inc. hold a median 12-month price target of $15 — +98.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$587.7M
Ticker Nerd rank
59 / 100
Median analyst target
$15
Analysts covering
5
Total return, dividends reinvested
1W
+1.3%
1M
−8.8%
YTD
−35.2%
1Y
−40.2%
From 52W high
−49.2%
From 52W low
+20.6%
$6
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CorMedix, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
59 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Quality
91
Growth
88
Size
52
Revisions
46
Volatility
43
Momentum
36
Accruals
27
Issuance
12

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CRMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Oct 25Jan 26Apr 26Jul 26CRMDHigh $19Median $15Low $13

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $13Median $15High $19

The green dot is the last close — the median target sits +98.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026RBC CapitalMaintainsOutperform$13 → $14
7 July 2026RBC CapitalMaintainsOutperform$14 → $13
28 Apr 2026CitizensReiteratesMarket Outperform—
28 Apr 2026Leerink PartnersMaintainsOutperform—
28 Apr 2026RBC CapitalMaintainsOutperform—
27 Apr 2026D. Boral CapitalMaintainsBuy—
27 Apr 2026NeedhamMaintainsBuy—
5 Mar 2026NeedhamMaintainsBuy—
11 Feb 2026D. Boral CapitalMaintainsBuy—
23 Jan 2026HC Wainwright & Co.MaintainsBuy—
21 Jan 2026RBC CapitalMaintainsOutperform—
8 Jan 2026D. Boral CapitalMaintainsBuy—
8 Jan 2026NeedhamMaintainsBuy—
18 Dec 2025D. Boral CapitalMaintainsBuy—
13 Nov 2025HC Wainwright & Co.MaintainsBuy—
12 Nov 2025D. Boral CapitalMaintainsBuy—
12 Nov 2025NeedhamMaintainsBuy—
21 Oct 2025RBC CapitalMaintainsOutperform—
20 Oct 2025D. Boral CapitalUpgradeBuy—
9 Sept 2025JMP SecuritiesReiteratesMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRMD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CRMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−35.9%
Analysts raising
1
Analysts cutting
0
Fundamentals

CorMedix, Inc. (CRMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.5×

Cheaper than 68% of US stocks

Price / sales
1.3×

Cheaper than 65% of US stocks

Price / book
1.4×

Cheaper than 62% of US stocks

EV / EBITDA
1.8×

Cheaper than 57% of US stocks

Growth & margins
Revenue growth (YoY)
156.5%

Higher than 95% of US stocks

Earnings growth (YoY)
31.1%

Higher than 67% of US stocks

Gross margin
82.5%

Higher than 92% of US stocks

Operating margin
42.1%

Higher than 93% of US stocks

Net margin
40.5%

Higher than 94% of US stocks

Returns & dividend
Return on equity
54.9%

Higher than 93% of US stocks

Return on assets
24.6%

Higher than 99% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CRMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CRMDCorMedix, Inc.$587.7M
59
NVCTNuvectis Pharma, Inc.$597.7M
68
EIKNEikon Therapeutics, Inc.$597.8M
2
VSTMVerastem, Inc.$578.0M
56
ARVNArvinas, Inc.$576.1M
84
ALTAltimmune, Inc.$571.4M
23
FDMT4D Molecular Therapeutics, Inc.$621.8M
54

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CorMedix, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRMD news & analysis

CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains

Zacks Investment Research · 14 Aug 2026positive

CorMedix shares rose 15% after the company reported second-quarter earnings and revenues that beat estimates, driven by solid utilization of DefenCath and contributions from the Melinta portfolio.

Why it matters — The earnings and revenue beat, aided by DefenCath utilization and Melinta contributions, signals improving commercial performance for CorMedix that CRMD watchers would note.

CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

CorMedix Inc. held its Q2 2026 earnings call, with a full transcript of the call published on Seeking Alpha. The transcript documents the company's second-quarter 2026 financial results and management commentary.

Why it matters — A CorMedix watcher would care because the earnings call transcript offers direct insight into the company's latest quarterly financial performance and management's perspective.

CorMedix Q2 Earnings Call Highlights

MarketBeat · 13 Aug 2026positive

CorMedix reported second-quarter 2026 consolidated revenue of $101.9 million and adjusted EBITDA of $58.7 million, while reaffirming its full-year revenue outlook and raising its adjusted EBITDA guidance. The company also signed a multiyear commercial supply agreement for DefenCath with an additional large dialysis organization, bringing it to supply agreements with each of the five largest U.S. dialysis providers.

Why it matters — CRMD watchers would care because the company expanded commercial coverage of DefenCath to all five largest U.S. dialysis providers, while raising EBITDA guidance supports its growth trajectory.

CorMedix Stock Jumps on Strong DefenCath Sales

Benzinga · 13 Aug 2026positive

CorMedix shares rose on Thursday after the company reported strong second-quarter results, driven by robust sales of its DefenCath product. The broader market was also slightly higher, with S&P 500 futures up 0.2%.

Why it matters — A CRMD watcher would care because strong DefenCath sales and solid Q2 results point to growing commercial traction for the company's lead product.

CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates

Zacks Investment Research · 13 Aug 2026positive

CorMedix reported Q2 earnings of $0.29 per share, surpassing the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.28 per share in the same quarter a year ago, with revenues also topping estimates.

Why it matters — The earnings beat shows CorMedix outperformed analyst expectations for the quarter, which is relevant for investors tracking the company's quarterly performance.

FAQ

Frequently asked questions about CRMD stock

What is the CRMD stock price forecast for 2026-2027?

The 5 Wall Street analysts covering CorMedix, Inc. have a median 12-month price target of $15, with estimates ranging from $13 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRMD stock a buy right now?

Of the 5 analysts covering CorMedix, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CorMedix, Inc. 59 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRMD?

As at 15 Aug 2026, CorMedix, Inc. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will CRMD stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +98.9% from the last close, and Ticker Nerd's factor model ranks CorMedix, Inc. 59 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRMD stock forecast for 2030?

No analyst covering CorMedix, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $19 over the next 12 months.

How has CRMD stock performed over the past year?

CorMedix, Inc. returned -40.2% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CorMedix, Inc. do?

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening conditions, particularly in anti-infective therapies and hospital-based treatments in the United States.

What is the latest news on CRMD?

The most recent item we track (Zacks Investment Research, 14 Aug 2026): "CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains". CorMedix shares rose 15% after the company reported second-quarter earnings and revenues that beat estimates, driven by solid utilization of DefenCath and contributions from the Melinta portfolio.

Company

About CorMedix, Inc.

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening conditions, particularly in anti-infective therapies and hospital-based treatments in the United States. Its lead product, DefenCath, is an FDA-approved antimicrobial catheter lock solution containing taurolidine and heparin, designed to reduce catheter-related bloodstream infections in adult patients with kidney failure undergoing chronic hemodialysis via central venous catheters. This product serves outpatient dialysis organizations and holds a unique position as the first such approved solution in its indication. Following the acquisition of Melinta Therapeutics in August 2025, CorMedix Inc. expanded its commercial portfolio to include seven innovative anti-infective drugs: MINOCIN for injection, REZZAYO for candidemia and invasive candidiasis, VABOMERE, ORBACTIV, BAXDELA, KIMYRSA, and TOPROL-XL. These therapies strengthen its presence in acute care settings, infectious disease management, and hospital markets, diversifying beyond dialysis applications. Incorporated in 2006 and headquartered in Berkeley Heights, New Jersey, CorMedix Inc. operates as a single drug product segment emphasizing commercial sales and strategic investments in specialty pharmaceuticals.

CEO Mr. Joseph Todisco MBA · 64 employees · United States · https://www.cormedix.com